CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$1.08 USD
-0.03 (-2.70%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Carisma Therapeutics Inc. [CARM]
Reports for Purchase
Showing records 1 - 11 ( 11 total )
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Three Combo Patients; Awaiting Full Dataset in 2Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
CT-0525 Takes Lead; CAR-M Combo Data 2Q24; 2023 Results; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First TIL Approval Validates Cell Therapy Class
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vivo CAR-M Candidate Nominated in Moderna Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Dosing CAR-Mono in 1H24; Potential Enhancements vs. CAR-M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
CAR-M + Keytruda Phase 1 Data in 1H24; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Moderna Partnership Data; Key CAR-M + Keytruda Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 CAR-M Bolus Dosing Data Shows Encouraging Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Two Defining Data Catalysts in 2H23; 2Q23 Financials; Raising PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Dosing Started in CAR-M+Keytruda Phase 1 Trial; Data by YE23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
It Takes CARisma to Lead in Cell Therapy; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
|